Needham, MA (PRWEB) April 11, 2012
The Drug Safety Executive Council™ (DSEC™) is pleased to announce that Dr. Ernie Bush, Director of Collaborative Projects, is a featured speaker at the 8th North American Drug Discovery Workshop, co-sponsored by Cyprotex. Dr. Bush’s presentation is entitled Industry Trends in Predictive Toxicology Technologies.
The session is sponsored by Cyprotex and its technology partners ChanTest (an ion channel company) and InSphero (a 3-D microtissue company), and will take place on April 12th from 8:30 a.m. to 5:30 p.m. at Le Meridien Cambridge Hotel in Cambridge, Massachusetts. Visit http://www.cyprotex.com for program agenda and registration details.
Dr. Bush’s talk will focus on predictive toxicology technologies, including highlighting the high interest from the pharmaceutical and biotech industry in using High Content Analysis tools and 3D cell culture technologies for predictive toxicology applications, as identified in the DSEC 4th Annual Survey – Technology Adoption in Drug Safety.
Of note, DSEC and Cambridge Healthtech Associates™ (CHA™), through the Technology Evaluation Consortium™ (TEC™), previously brought together 10 major pharmaceutical companies to conduct the initial qualification and validation of CellCiphr™, Cyprotex’s high-content cell health assay technology. The TEC program is designed to ensure new technologies for drug discovery and development are optimized for the pharmaceutical research community.
The Drug Safety Executive Council™ (DSEC™) is an online community focused on the development of better and safer medicines. DSEC is a platform for biopharmaceutical companies, contract research organizations, governmental entities and academic institutions to share knowledge and exchange ideas on improving drug safety assessment. Visit http://www.drugsafetycouncil.org.
DSEC™ is managed by Cambridge Healthtech Associates™ (CHA™), a firm that uses its collaborative model to improve the speed and economics of life science R&D, leveraging its consulting, technology evaluations and communities. Visit http://www.chacorporate.com.
Cyprotex was founded in 1999 and headquartered in Macclesfield, UK. With its 2010 acquisition of Apredica, a Watertown, US-based pioneer in predictive toxicology and customised ADME research, Cyprotex now has operations on two continents. Cyprotex has developed proprietary technologies for highly automated in vitro ADME screening (Cloe® Screen), in vitro high content imaging assessment of mechanistic toxicity (CellCiphr™), in silico PBPK modelling (Cloe® PK) for estimating whole-body exposure, and genomic ADME (gADME™) program for defining metabolic pathways and identifying the impact of genetic polymorphisms. Cyprotex’s services take a consultative, collaborative approach that includes custom assay development and emphasizes fast turnaround times. Cyprotex also provides ancillary services through collaborations with partner companies. Cyprotex collaborates with Sygnature Discovery to provide integrated drug discovery services, and with Solvo Biotechnology for drug transporter assays. Over 700 drug, agrochemical, and cosmetic discovery organisations in 31 countries -- including large pharmaceutical companies, virtual companies, and academic and not-for-profit organizations -- trust Cyprotex for their ADME Tox research needs.